Q3 gross loss exceeded our expectations, but we reiterate our estimates for 2026 and beyond. Curasight remains on track to initiate its ph1 trial of uTREAT in glioblastoma in H2/25 (with enrolment now open), and the ph2 uTRACE trial is actively recruiting across all sites. We expect data from the glioblastoma trial to begin to come in Q4/25. This is a potential de-risking event. We reiterate our DKK 14-36 per share valuation range.
LÄS MER
